Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL30789018 | 0.86 | SLC22A1 (0.52) | SLC22A1KCNH2EPHX1SLC22A2TSHR | |
| Tetrapentylammonium SCHEMBL2862362 | 0.86 | SLC22A1 (0.52) | SLC22A1KCNH2SLC22A2TSHR | |
| Tetrabuthylammonium SCHEMBL160605 | 0.86 | SLC22A1 (0.52) | SLC22A1KCNH2EPHX1SLC22A2TSHR | |
| Tetrahexylammonium SCHEMBL2862380 | 0.85 | SLC22A1 (0.54) | SLC22A1KCNH2SLC22A2TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL28812353 | 0.85 | SLC22A1 (0.54) | SLC22A1KCNH2SLC22A2TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL2857295 | 0.85 | SLC22A1 (0.54) | SLC22A1KCNH2SLC22A2TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL27033917 | 0.84 | BBOX1 (0.41) | KCNH2EPHX1ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL6895412 | 0.84 | KCNH2 (0.37) | KCNH2EPHX1ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL302110 | 0.83 | SLC22A1 (0.52) | SLC22A1KCNH2SLC22A2TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL28585900 | 0.83 | SLC22A1 (0.52) | SLC22A1KCNH2SLC22A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135499-A1 | PROCESS FOR ROXADUSTAT USING NOVEL INTERMEDIATES | OPTIMUS DRUGS PVT LTD (IN) | 2023-07-20 | — | — | WO | claimed |
| US-9242926-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2016-01-26 | — | — | US | claimed |
| US-8853439-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2014-10-07 | — | — | US | claimed |
| US-20140296572-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-10-02 | — | — | US | claimed |
| US-20130123537-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | AUROBINDO PHARMA LTD. (IN) | 2013-05-16 | — | — | US | claimed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | claimed |
| US-20120209022-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2012-08-16 | — | — | US | claimed |
| EP-2480524-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2012-08-01 | — | — | EP | claimed |
| WO-2011144983-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE | AUROBINDO PHARMA LIMITED (IN) | 2011-11-24 | — | — | WO | claimed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | claimed |
| WO-2011039781-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-04-07 | — | — | WO | claimed |
| US-20260118767-A1 | REVERSE PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4700067-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING FILM, METHOD FOR FORMING FILM, AND SUPERSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20260044081-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4692941-A2 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-6359102-B1 | ADMIXING AN AQUEOUS SOLUTION COMPRISING A FIRST MONOMER WITH A WATER-IMMISCIBLE ORGANIC SOLVENT; CATALYST SELECTED FROM TERTIARY AMINE, QUATERNARY AMINE AND PHOSPHONIUM CATALYSTS, ACID SCAVENGER AND ACID FORMING COMONOMER; RECOVERING | INTEGRA LIFESCIENCES I, LTD. | 2002-03-19 | — | — | US | disclosed |
| EP-0391212-B1 | Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers | BAYER AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5136013-A | Polyesters | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0459258-A2 | Process for the preparation of olefinic and acetylenic compounds | BAYER AG (DE) | 1991-12-04 | — | — | EP | disclosed |
| US-5068300-A | BIFUNCTIONAL STILBENE COMPOUNDS CONTAINING AT LEAST ONE Z-CONFIGURATED STILBENE GROUP, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123537-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | MYT1, TET1, LPXN | SLC22A1 2105/4885KCNH2 407/4885EPHX1 3434/4885 |
| US-20120209022-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CA3, TREH, NAAA | SLC22A1 2368/4885KCNH2 420/4885EPHX1 2520/4885 |
| US-20260118767-A1 | REVERSE PATTERNING PROCESS | EFNA1, EPHA4, ETV6 | SLC22A1 4619/4885KCNH2 758/4885EPHX1 1683/4885 |
| US-20260044081-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS | SMC1A, SPOUT1, LBR | SLC22A1 2467/4885KCNH2 2302/4885EPHX1 3013/4885 |
| US-20140296572-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CA3, TREH, NAAA | SLC22A1 2368/4885KCNH2 420/4885EPHX1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.